New EU Approvals
Executive Summary
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with two new products including Astellas Pharma's Xospata (gilteritinib) for treating relapsed or refractory acute myeloid leukemia. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).